Tim Walbert, Horizon Therapeutics CEO (via YouTube)
November 30, 2022 05:53 AM ESTUpdated December 9, 03:02 AM
Deals

Hori­zon Ther­a­peu­tics in takeover talks with Am­gen, J&J, Sanofi as po­ten­tial buy­ers

Amber Tong

Am­gen, J&J’s Janssen and Sanofi are all in talks to ac­quire Hori­zon Ther­a­peu­tics, the rare dis­ease biotech dis­closed late Tues­day.

Hori­zon con­firmed “

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Deputy FDA chief mulls shak­ing up PDU­FA reau­tho­riza­tion struc­ture

Up­dat­ed: No­vo Nordisk CEO to step down amid stock de­cline, time­line for suc­ces­sor un­known

The in­side sto­ry of the six-month sprint to cre­ate the first cus­tom CRISPR ther­a­py for one in­fant’s rare dis­ease

Low­er at­ten­dance at cell and gene ther­a­py con­fer­ence mir­rors chal­lenged in­dus­try

Bris­tol My­ers CEO says Amer­i­ca’s bio­phar­ma pole po­si­tion is not guar­an­teed

No­vo Nordisk’s glob­al obe­si­ty leader is mov­ing on; Flag­ship biotech gets CEO from Schol­ar Rock

A service from the Financial Times